What did @tru.md actually say?
The creator made a specific mechanistic argument: BPC-157 works for tendon injuries because it upregulates VEGF and other growth factors, which increases blood flow to tissue that already has poor vascularization. Tendons heal slowly, the reasoning goes, because they don't bleed much. BPC-157 theoretically fixes that bottleneck. He also positioned tendinopathy as "probably the best case" for using these peptides, which is a strong claim worth examining carefully.
To be fair, the framing was reasonably cautious. He said "in theory" and "many times faster in theory," which is more honest than most peptide content on TikTok. He did not promise a cure, did not give a dosing protocol, and did not claim this replaces rehabilitation. That matters.
Does the science back this up?
Partially, but the evidence is almost entirely preclinical. The VEGF mechanism is real in animal models. Whether it translates to humans with hamstring tendinopathy is genuinely unknown.
The VEGF upregulation claim has support in rodent studies. Chang et al. (2011, Journal of Applied Physiology) showed BPC-157 accelerated tendon-to-bone healing in rats, with measurable increases in growth factor expression. Gwyer et al. (2019, Current Pharmaceutical Design) reviewed the broader evidence and concluded BPC-157 promotes angiogenesis and wound healing in animal models, but flagged the absence of human clinical trials as a serious gap. For TB-500, which the creator mentioned but barely discussed, Philp et al. (2004, Journal of Cell Science) documented thymosin beta-4's role in actin sequestration and cell migration, relevant to tissue repair, again in non-human models. There are no published randomized controlled trials in humans for either peptide as of 2024.
What did they get wrong (or right)?
The anatomy explanation was mostly right. Tendons do have significantly lower vascularization than muscle, and this does contribute to slower healing. That's not controversial. The creator's description of tendons connecting muscle to bone (and ligaments connecting bone to bone) was accurate, though he conflated the two briefly when he said "connects two bones together or a muscle to a bone" in the same breath about tendons.
Where the argument gets shaky is the leap from "BPC-157 increases VEGF in rats" to "this will help increase blood flow" in a human hamstring. Tendinopathy is not a simple vascular deficiency problem. Chronic tendinopathy often involves degenerative changes, collagen disorganization, and neovascularization that is already present but dysfunctional (Cook and Purdam, 2009, British Journal of Sports Medicine). More blood flow is not always the answer. The mechanism the creator described is plausible but oversimplified, and applying it to chronic tendinopathy specifically requires more nuance than the video offers.
The phrase "many times faster" is doing a lot of work with no human data to support it.
What should you actually know?
BPC-157 and TB-500 are not FDA-approved treatments. They are available in the U.S. primarily as research chemicals or through compounding pharmacies, and their regulatory status has been contested. The FDA placed BPC-157 on its list of substances that cannot be compounded under Section 503A in 2022, though enforcement remains uneven.
If you have hamstring tendinopathy, the treatments with actual human evidence behind them are progressive loading programs (specifically eccentric and heavy slow resistance training), which have strong RCT support (Beyer et al., 2015, American Journal of Sports Medicine). Platelet-rich plasma has mixed evidence. Peptides do not have human trial evidence for this indication.
That does not mean BPC-157 definitely does not work. It means we do not know. There is a difference. The creator presented a mechanistic hypothesis as something close to established fact, and that gap between hypothesis and evidence is where patients make decisions they may later regret, or waste money, or delay interventions that are actually proven.
Bottom line
The creator got the basic biology mostly right and was more careful with his language than most peptide promoters. The VEGF mechanism is real in animals. But the jump from rat tendon data to human hamstring tendinopathy treatment is a significant one, and the video does not make that gap clear enough. Tendinopathy is also more complex than a vascular supply problem. Take the mechanism discussion as interesting background, not a treatment plan.